» Articles » PMID: 35052557

Maladaptive Pulmonary Vascular Responses to Chronic Sustained and Chronic Intermittent Hypoxia in Rat

Overview
Date 2022 Jan 21
PMID 35052557
Authors
Affiliations
Soon will be listed here.
Abstract

Chronic sustained hypoxia (CSH), as found in individuals living at a high altitude or in patients suffering respiratory disorders, initiates physiological adaptations such as carotid body stimulation to maintain oxygen levels, but has deleterious effects such as pulmonary hypertension (PH). Obstructive sleep apnea (OSA), a respiratory disorder of increasing prevalence, is characterized by a situation of chronic intermittent hypoxia (CIH). OSA is associated with the development of systemic hypertension and cardiovascular pathologies, due to carotid body and sympathetic overactivation. There is growing evidence that CIH can also compromise the pulmonary circulation, causing pulmonary hypertension in OSA patients and animal models. The aim of this work was to compare hemodynamics, vascular contractility, and L-arginine-NO metabolism in two models of PH in rats, associated with CSH and CIH exposure. We demonstrate that whereas CSH and CIH cause several common effects such as an increased hematocrit, weight loss, and an increase in pulmonary artery pressure (PAP), compared to CIH, CSH seems to have more of an effect on the pulmonary circulation, whereas the effects of CIH are apparently more targeted on the systemic circulation. The results suggest that the endothelial dysfunction evident in pulmonary arteries with both hypoxia protocols are not due to an increase in methylated arginines in these arteries, although an increase in plasma SDMA could contribute to the apparent loss of basal NO-dependent vasodilation and, therefore, the increase in PAP that results from CIH.

Citing Articles

Pulmonary Vascular Responses to Chronic Intermittent Hypoxia in a Guinea Pig Model of Obstructive Sleep Apnea.

Olea E, Valverde-Perez E, Docio I, Prieto-Lloret J, Aaronson P, Rocher A Int J Mol Sci. 2024; 25(13).

PMID: 39000591 PMC: 11242077. DOI: 10.3390/ijms25137484.


Understanding human aging and the fundamental cell signaling link in age-related diseases: the middle-aging hypovascularity hypoxia hypothesis.

Phua T Front Aging. 2023; 4:1196648.

PMID: 37384143 PMC: 10293850. DOI: 10.3389/fragi.2023.1196648.


Intermittent Hypoxia and Diet-Induced Obesity on the Intestinal Wall Morphology in a Murine Model of Sleep Apnea.

Valverde-Perez E, Olea E, Obeso A, Prieto-Lloret J, Rocher A, Gonzalez-Obeso E Adv Exp Med Biol. 2023; 1427:89-97.

PMID: 37322339 DOI: 10.1007/978-3-031-32371-3_10.


Inflammation and immunity in the pathogenesis of hypoxic pulmonary hypertension.

Ye Y, Xu Q, Wuren T Front Immunol. 2023; 14:1162556.

PMID: 37215139 PMC: 10196112. DOI: 10.3389/fimmu.2023.1162556.


Oxygen Sensing: Physiology and Pathophysiology.

Aaronson P, Rocher A Antioxidants (Basel). 2022; 11(5).

PMID: 35624881 PMC: 9138106. DOI: 10.3390/antiox11051018.


References
1.
MacLean M, Morecroft I . Increased contractile response to 5-hydroxytryptamine1-receptor stimulation in pulmonary arteries from chronic hypoxic rats: role of pharmacological synergy. Br J Pharmacol. 2001; 134(3):614-20. PMC: 1572973. DOI: 10.1038/sj.bjp.0704273. View

2.
Millatt L, Whitley G, Li D, Leiper J, Siragy H, Carey R . Evidence for dysregulation of dimethylarginine dimethylaminohydrolase I in chronic hypoxia-induced pulmonary hypertension. Circulation. 2003; 108(12):1493-8. DOI: 10.1161/01.CIR.0000089087.25930.FF. View

3.
Nisbet R, Graves A, Kleinhenz D, Rupnow H, Reed A, Fan T . The role of NADPH oxidase in chronic intermittent hypoxia-induced pulmonary hypertension in mice. Am J Respir Cell Mol Biol. 2008; 40(5):601-9. PMC: 2677439. DOI: 10.1165/2008-0145OC. View

4.
Galie N, Hoeper M, Humbert M, Torbicki A, Vachiery J, Barbera J . Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the.... Eur Heart J. 2009; 30(20):2493-537. DOI: 10.1093/eurheartj/ehp297. View

5.
Pinheiro L, Tanus-Santos J, Castro M . The potential of stimulating nitric oxide formation in the treatment of hypertension. Expert Opin Ther Targets. 2017; 21(5):543-556. DOI: 10.1080/14728222.2017.1310840. View